Navigation Links
Sales of HER2-Targeting Agents for Breast Cancer, Including Herceptin and Tykerb/Tyverb, Will Grow by 3.3 Percent Annually from 2008 to 2018
Date:11/9/2009

WALTHAM, Mass., Nov. 9 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in 2008, human epidermal growth factor receptor 2 (HER2) targeting therapies -- which include Roche/Chugai's Herceptin and GlaxoSmithKline/Nippon Kayaku's Tykerb/Tyverb -- were the highest-selling drug class in breast cancer treatment. Continued uptake of Herceptin and Tykerb/Tyverb and the expected launches of three new therapies will drive sales of HER2-targeting agents to grow by 3.3 percent per year from 2008 to 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Breast Cancer finds that significant declines in sales in the hormonal therapy and chemotherapy segments of the market will be offset by a 1.2 percent annual increase in breast cancer incidence in the world's major markets and by the launch and uptake of premium-priced agents. Emerging HER2-targeting therapies that are expected to launch by 2018 include Roche/Chugai's Omnitarg, Roche's T-DM1 and Wyeth's HKI-272.

The report also finds that sales of Roche/Chugai's Avastin for breast cancer will increase by four percent from 2008 to 2018, largely owing to greater uptake by patients with metastatic disease.

"Since its approval, Avastin has garnered substantial patient share in metastatic breast cancer, particularly in the metastatic triple-negative and metastatic HR-refractory treatment settings, where there is a significant need for effective therapeutic options," said Decision Resources Analyst Niamh Murphy, Ph.D. "However, many of the physicians we interviewed, particularly in Europe, are not very enthusiastic about Avastin for breast cancer because they consider its cost-benefit profile suboptimal."

According to the report, experts are enthusiastic about the launch and uptake of a novel class of breast cancer
'/>"/>

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Recession Continues to Depress Sales at Allied Healthcare Products
2. Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent
3. Prasco Enters into Agreements with sanofi-aventis U.S. to Provide Sales Support and Distribution Services for Authorized Generic Versions Under the Winthrop Label in U.S.
4. DUSA Pharmaceuticals Surpasses One Million in Cumulative Levulan(R) Kerastick(R) Sales Units
5. Cephalon Net Sales Increase 9% and Net Cash from Operations Surpasses $200 Million in the Third Quarter 2009
6. HeartSine and Your Safety Company to Donate a Portion of Sales Proceeds to Sudden Cardiac Arrest Foundation
7. University Medical Pharmaceuticals Selects Jeffrey Ten as Senior Vice President, International Sales
8. Biosimilar Insulins and Insulin Analogues Stand to Erode $6.1 Billion in Brand Sales in the U.S. and Europe by 2018
9. Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery
10. $500 Billion Health Care Spend Boosts BRIC Countries Diagnostic Imaging Sales Despite Global Recession, According to Millennium Research Group
11. EUCODIS Bioscience Appoints Bhupinder Hundle to Senior Vice President Marketing & Sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015 Roughly ... or very confident substituting an interchangeable biosimilar for ... share the same nonproprietary name, according to a ... Pharmacy,s (AMCP,s) Journal of Managed Care & ... about 25 percent of pharmacists would feel as ...
(Date:2/27/2015)... -- WuXi PharmaTech (Cayman) Inc. (NYSE:  WX), a leading ... pharmaceutical, biotechnology, and medical device industries with operations in ... United States , congratulates our partner TaiMed Biologics ... for ibalizumab (TMB355). The FDA designates a drug as ... in combination with one or more other drugs, to ...
(Date:2/27/2015)... -- Acsis Inc., the market leader for supply chain visibility, ... John DiPalo , Acsis, Chief Strategy Officer, has been ... 2015 Provider Pro to Know. The award recognizes ... prepare their companies, and customers, supply chains for the ... of Provider Pros to Know is featured in ...
Breaking Medicine Technology:Survey Published in AMCP's JMCP Finds Pharmacists Are Most Confident Substituting Interchangeable Biosimilars for Brand Biologics When Products Share Nonproprietary Name 2WuXi Congratulates TaiMed Biologics on Receiving Breakthrough Therapy Designation from U.S. FDA 2Acsis CSO John DiPalo Named Supply & Demand Chain Executive 2015 Pro to Know 2
(Date:2/28/2015)... 28, 2015 The Classic Denture ... a new special. Throughout all of March patients ... , This service can help overall mouth ... pain. Patients may notice certain symptoms that suggest the ... These symptoms include: , 1.    Pain, clicking, and popping in ...
(Date:2/28/2015)... Vancouver, BC (PRWEB) February 28, 2015 Vancouver ... several personal injury claims are affected by time limits. They ... can weaken a person’s claim or even nullify it. Many ... adverse effects on a client’s rights under BC law. As ... who are affected by accidents should consult a personal injury ...
(Date:2/28/2015)... February 28, 2015 For those people ... person, the Mesothelioma Applied Research Foundation (Meso ... Tuesday, March 3, starting at 9:30 AM. , The ... registration. The broadcast can be accessed through any browser ... . , The Symposium is a unique event that ...
(Date:2/28/2015)... Louis, MO (PRWEB) February 28, 2015 ... leading provider of outsourced sales, marketing and supply ... their client, BIOTA Botanicals, is bringing its award ... Celebrated worldwide, BIOTA Botanicals’ products are specifically created ... herbal care experts, BIOTA is committed to marrying ...
(Date:2/28/2015)... February 28, 2015 A case management ... lawsuits that have been filed by law firms including ... week in March, the Firm notes. , According ... involved in the federal litigation will meet on March ... to prescription therapy treatments designed to raise levels of ...
Breaking Medicine News(10 mins):Health News:Classic Denture Center in Portland Oregon is Offering March Discount 2Health News:Jiwa Law Corporation Recently Announced That Time Delays May Weaken Personal Injury Claims 2Health News:Mesothelioma Cancer Research Foundation Broadcasting Symposium Live 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 2Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 3Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 4
... and anxiety are the heaviest smokers in the country, but ... assume that if their patients try to quit smoking, their ... a myth, according to Brian Hitsman, a tobacco addiction specialist ... School of Medicine. He also is a member of the ...
... Growing evidence shows that exposure to lead in the ... of hypertension. However, those studies have looked at lead ... of cumulative lead exposure over time. In a new ... (HSPH) and the University of Michigan School of Public ...
... a new report, University of Illinois professor Barbara H. Fiese urges ... family mealtimes as a matter of public policy. "There are ... their families as taking 18 to 20 minutes to eat together ... said Fiese, a U of I professor of human development and ...
... , , , ... of the nation,s leading experts in asthma, has been ... Erzurum will collaborate with experts in nuclear medicine and ... observe changes in the lungs of patients during an ...
... WASHINGTON, Sept. 9 As Obama prepares to address the nation ... nation,s Catholic bishops to be prepared to shut down Catholic health ... compromising with the intrinsic evils currently contained in various Obamacare proposals. ... ) , , "Obama speaks tonight. ...
... , BOSTON, Sept. 9 A ... a result of laboratory use and confinement. Developmental Context ... published in the September issue, Vol. 45 (5), of the ... . , , (Photo: http://www.newscom.com/cgi-bin/prnh/20090909/DC72238 ) ...
Cached Medicine News:Health News:Doctors fear asking mentally ill to quit smoking 2Health News:Doctors fear asking mentally ill to quit smoking 3Health News:Lead in bone associated with increased risk of death from cardiovascular disease in men 2Health News:U of I acientist: Public policy should promote family mealtimes 2Health News:U of I acientist: Public policy should promote family mealtimes 3Health News:$750,000 Awarded for Cutting-Edge Asthma Research to 'See' Changes in the Lungs During an Attack 2Health News:A.L.L.: Bishops Must Choose Between Christ-Centered Care and Obamacare 2Health News:Chimpanzees Suffer Psychologically Like Humans 2Health News:Chimpanzees Suffer Psychologically Like Humans 3
This 1000 L tip is the equivalent to the "Blue" tips and fits nearly every manufacturer's 1000 L pipettor....
This 500 tip allows you to draw the full volume of compatible Biohit and Eppendorf pipettors....
Ambion's barrier tips prevent cross-contamination of samples by means of an aerosol filter. They are RNase- and DNase-free and are ideal for handling RNA, PCR applications, and for working with radio...
MBP's 200 ul large orifice tip is perfect for handling fragile cells, viscous samples, and genomic DNA....
Medicine Products: